INNOVATION in COVID-19

WHAT THE GLOBAL PANDEMIC HAS TAUGHT US AS WE PREPARE FOR THE NEXT GLOBAL HEALTH CHALLENGE.

American biopharmaceutical companies have been working around the clock for more than a year with the primary objective of ending the pandemic. These efforts, made possible through unprecedented collaborations, have resulted in multiple vaccines and treatments receiving emergency use authorization for use in the United States including one treatment receiving approval for the treatment of severe COVID-19 infection.

AMERICANS APPRECIATE INDUSTRY’S ROLE IN ADVANCING INNOVATION, through development of COVID-19 vaccines and treatments, as well as testing existing medicines to help those infected with the virus.

- The majority of Americans (86%) agree the industry has made good progress in the search for a coronavirus treatment or vaccine.\(^i\)
- 87% of Americans agree the coronavirus pandemic has shown the important role drug companies have in research and development for discovering new treatments, cures and vaccines.\(^i\)
- Americans also recognize the industry’s role within the American innovation ecosystem, with 78% believing government should work more closely with the biopharmaceutical industry to develop treatments and a vaccine for the coronavirus.\(^i\)
- Overall, total favorability for the biopharmaceutical industry nearly doubled between January 2020 (32%) and February 2021 (62%).\(^i\)

AMERICANS VIEW A STRONG BIOPHARMACEUTICAL INDUSTRY AS A VITAL STRATEGIC ASSET, essential for protecting us against future pandemics.

- 89% of voters support keeping a strong and resilient health care system is important to protect against future pandemics.\(^i\)
- Americans don’t want to cede biopharmaceutical leadership to other nations – 77% of voters think that a strong American biopharmaceutical industry is a matter of national security.\(^i\)

INDUSTRY INVESTMENT IN RESEARCH AND DEVELOPMENT OF THE COVID-19 VACCINES is expected to have a high return on investment for the economy, both in reduced fiscal costs and in renewed economic activity.

- Economists estimate that speeding up the vaccines’ arrival by six months to January 2021 is worth approximately $1.8 trillion.\(^\text{vii}\)
- Current estimates also state that industry infrastructure to produce 3 billion vaccine courses per year has a global benefit of $17.4 trillion.\(^\text{viii}\)
- Prioritizing investment in vaccine doses is also expected to be a beneficial economic decision. On the other hand, Europe’s emphasis on negotiating the price of COVID-19 vaccine doses may ultimately be “a perceived short-term pricing advantage at the expense of everything else.” Each $1 saved per vaccine dose might total $1 billion in economic and societal costs due to delayed access.\(^\text{ix}\)

To end the pandemic while preparing for the challenges ahead, we need to continue the ROBUST RESEARCH AND DEVELOPMENT ECOSYSTEM including a STRONG BIOPHARMACEUTICAL INDUSTRY that has helped fight COVID-19 in record time.

\(^i\) Public Opinion Strategies December 2020 Poll
\(^ii\) Public Opinion Strategies December 2020 Poll
\(^iii\) The Harris Poll March 2021
\(^iv\) November 2020 Morning Consult Tracking Poll
\(^v\) November 2020 Morning Consult Tracking Poll
\(^vi\) November 2020 Morning Consult Tracking Poll